Back

JAK1/2 inhibitor ruxolitinib restores the responsiveness to hypoxia in pulmonary arterial hypertension-iPSC-derived endothelial cells

29 August 2017 (12:03 - 12:12)
Organised by:
Congress Presentation Part of: Progress in the management of pulmonary hypertension Chronic pulmonary hypertension ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Mark Johannes Lachmann

Hospital right the Isar, Munich (Germany)

9 More presentations in this session

Presentation thumbnail
Subcutaneous treprostinil for the treatment of non-operable chronic thromboembolic pulmonary hypertension: a randomized, controlled trial (CTREPH)
Doctor R. Sadushi-Kolici (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
A phase 3 study in an enriched population of pulmonary arterial hypertension patients with long term oxygen use demonstrating improved exercise tolerance with use of ambulatory inhaled nitric oxide
Doctor H. Farber (Bollington, GB)
Abstract Slides Video
Presentation thumbnail
Comparative receptor pharmacology, pre-clinical efficacy and pharmacokinetics of a novel, next-generation prostacyclin receptor agonist, ralinepag (APD811), in humans and rats
Doctor J. Adams (San Diego, US)
Abstract
Presentation thumbnail
Cardiac magnetic resonance characterization of maladaptive right ventricular hypertrophy in chronic pulmonary hypertension.
Doctor I. Garcia Lunar (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
APD811 (ralinepag), a novel non-prostanoid IP receptor agonist, has potent antiproliferative and vasorelaxant properties in human pulmonary artery
Doctor J. Patel (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Progress in the management of pulmonary hypertension

The Event

Event poster

ESC Congress 2017

29 August 2017 12:03 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources